Novartis | NVS - Ebit


Novartis reported $4.18B in EBIT for its fiscal quarter ending in March of 2026.





Ebit Change Date
AbbVie USD 6.72B 1.99B Jun/2026
Amgen USD 4.61B 777M Jun/2026
AstraZeneca USD 3.16B 3.95B Jun/2026
Bausch Health Companies USD 776M 287M Jun/2026
Biogen USD -243.8M 758.1M Jun/2026
Bristol-Myers Squibb USD 299M 3.26B Jun/2026
Canopy Growth CAD -145.65M 132.99M Mar/2026
Corcept Therapeutics USD 41.3M 90.9M Jun/2026
Drreddys Laboratories INR 3.05B 13.32B Mar/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
GlaxoSmithKline GBP 2.6B 312M Jun/2026
Glaxosmithkline GBP 2.31B 14.92M Mar/2026
J&J USD 6.47B 1B Sep/2026
Merck USD 840M 2.72B Jun/2026
Novartis USD 4.73B 549M Jun/2026
Novartis USD 4.18B 118M Mar/2026
Pacira USD 9.96M 5.33M Jun/2026
Perrigo USD 33.6M 50.8M Mar/2026
Pfizer USD -180M 5.16B Jun/2026
Phibro Animal Health USD 54.99M 2.36M Dec/2025
Prestige Brands USD 52.52M 22.97M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sanofi EUR 1.12B 811M Jun/2026
Sanofi EUR 2.18B 1.56B Mar/2026
Supernus Pharmaceuticals USD -21.04M 14.21M Jun/2026
Zoetis USD 1.12B 279M Jun/2026